Oncorena is aiming to save human lives by transforming a natural substance into a breakthrough therapy treatment for advanced kidney cancer. We have completed all preclinical studies and are moving into early-stage clinical development. The objective is to confirm the powerful anti-tumor activity of our drug candidate - based on the natural substance orellanine - in advanced kidney cancer patients. Oncorena AB is headquartered in Lund, Sweden.